Champions Oncology (CSBR) Assets Average (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Assets Average of $27.7 million for Q2 2026, down 11.97% year-over-year from $31.5 million in Q2 2025, and down 5.41% quarter-over-quarter from $29.3 million in Q1 2026.
Champions Oncology (CSBR) Assets Average (2011 - 2026) Analysis & Trends
Champions Oncology's Assets Average history runs 16 years deep, the most recent figure standing at $27.7 million for Q2 2026.
- In Q2 2026, Assets Average fell 11.97% year-over-year to $27.7 million; the TTM figure through Apr 2026 stood at $27.7 million (down 11.97% YoY), while the FY2026 annual figure was $29.7 million, up 1.47% from the prior year.
- Assets Average for Q2 2026 stood at $27.7 million, down from $29.3 million in the prior quarter.
- The five-year high for Assets Average was $36.3 million in Q1 2023, with the low at $25.1 million in Q4 2024.
- The 5-year median for Assets Average is $30.9 million (2022), against an average of $30.7 million.
- The sharpest annual moves came in 2022 and 2024: Assets Average soared 30.48% in 2022, then dropped 24.9% in 2024.
- Champions Oncology's Assets Average stood at $35.4 million in 2022, then retreated by 17.74% to $29.1 million in 2023, then fell by 13.79% to $25.1 million in 2024, then advanced by 21.0% to $30.4 million in 2025, then dropped by 8.68% to $27.7 million in 2026.
- Business Quant data shows CSBR's Assets Average at $27.7 million in Q2 2026, $29.3 million in Q1 2026, and $30.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 27.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 27.72 Mn |
| Jan 31, 2026 | 29.30 Mn |
| Oct 31, 2025 | 30.35 Mn |
| Jul 31, 2025 | 31.45 Mn |
| Apr 30, 2025 | 31.49 Mn |
| Jan 31, 2025 | 27.93 Mn |
| Oct 31, 2024 | 25.09 Mn |
| Jul 31, 2024 | 25.53 Mn |
| Apr 30, 2024 | 26.46 Mn |
| Jan 31, 2024 | 27.54 Mn |
| Oct 31, 2023 | 29.10 Mn |
| Jul 31, 2023 | 32.11 Mn |
| Apr 30, 2023 | 35.23 Mn |
| Jan 31, 2023 | 36.26 Mn |
| Oct 31, 2022 | 35.38 Mn |
| Jul 31, 2022 | 34.88 Mn |
| Apr 30, 2022 | 34.48 Mn |
| Jan 31, 2022 | 31.44 Mn |
| Oct 31, 2021 | 28.70 Mn |
| Jul 31, 2021 | 27.85 Mn |